Drugs / CRB-601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06603844 | Dec 2024 → Nov 2026 expected | cancer | Corbus Pharmaceuticals Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-01-09 | Corbus Pharmaceuticals Inc. | Regulatory Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601) corbuspharma.com ↗
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. |
| 2023-11-02 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting corbuspharma.com ↗
Results showed: CRB-601 demonstrated immunomodulatory effects as reflected in changes in cytotoxic CD8+ T cell population and gene expression in the TME. |
| 2023-04-17 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting corbuspharma.com ↗
CRB-601 exhibited dose dependent tumor growth inhibition (TGI) in the EMT6 tumor model which was significantly augmented in combination with anti-PD1 therapy. |
| 2022-11-10 | Corbus Pharmaceuticals Inc. | Results Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting corbuspharma.com ↗
The latest preclinical data demonstrate significant tumor growth inhibition by CRB-601 as a single agent and in combination with anti-PD-1 treatment in the syngeneic murine tumor models MC38 and EMT6. |
| 2022-05-11 | Corbus Pharmaceuticals Inc. | Results Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference corbuspharma.com ↗
The latest preclinical data for CRB-601 demonstrate its significant effects on inhibiting tumor growth as a single agent and in combination with anti-PD-1 treatment in the MC38 and EMT6 syngeneic tumor models. |
| 2022-04-08 | Corbus Pharmaceuticals Inc. | Results Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting corbuspharma.com ↗
The in vitro preclinical data presented demonstrate the high affinity of CRB-601 for αvb8 and the resulting effect on TGFb. |
| 2021-08-12 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates corbuspharma.com ↗
CRB-601 is also up to 10x more potent in vitro than its precursor mAb, C6D4. |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRB-601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06603844 ↗ |
| Modality | Monoclonal antibody | “CRB-601, a Monoclonal Antibody Against Integrin avb8” NCT06603844 ↗ |
| Route | Intravenous | “administered intravenously” NCT06603844 ↗ |